Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419989 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL30842608 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL937543 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL3490337 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL30288493 | 1.00 | PNMT (0.61) | PNMTSLC6A2SLC6A4TAAR1MAPT | |
| SCHEMBL23489619 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL20833722 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL7783860 | 0.82 | CES2 (0.49) | PNMTSLC6A2SLC6A4CES2CES1 | |
| SCHEMBL30988818 | 0.82 | CES2 (0.49) | SLC6A2SLC6A4CYP3A4CES2CES1 | |
| SCHEMBL17660052 | 0.82 | CES2 (0.49) | SLC6A2SLC6A4CYP3A4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112601749-A | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | PNMT 689/4885SLC6A2 1243/4885SLC6A4 1330/4885 |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | PNMT 689/4885SLC6A2 1243/4885SLC6A4 1330/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | PNMT 689/4885SLC6A2 1243/4885SLC6A4 1330/4885 |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | PNMT 689/4885SLC6A2 1243/4885SLC6A4 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.